FDA Approves Unknown Drug — HETERO LABS LTD III

# FDA Approves Generic Drug Application for Hetero Labs Hetero Labs Ltd III received FDA approval for an abbreviated new drug application (ANDA218264) on March 12, 2026, positioning the manufacturer to capture market share in the generic segment. The approval expands Hetero Labs' U.S. pharmaceutical portfolio and could intensify pricing competition in its therapeutic category once the product reaches market.